Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

March 30, 2020

Merck’s vericiguat meets primary endpoint in VICTORIA trial

Merck said that its orally administered soluble guanylate cyclase (sGC) stimulator vericiguat met the primary efficacy endpoint in the phase 3 VICTORIA trial in heart failure patients.

Merck’s vericiguat meets primary endpoint in VICTORIA trial